Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Zaffaroni

Showing results (41-50 of 234) with videos related to

Pageof 24
Sort By:
Current Topics in Medicinal Chemistry|December 27, 2011
RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapyMarzia Pennati, Enrico Millo, Paolo Gandellini, et al.
BMC Cancer|June 8, 2010
Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysisLorenza Venturini, Rosita Motta, Alessandro Gronchi, et al.
Current Medicinal Chemistry|February 16, 2013
MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targetsNicola Fenderico, Anna Casamichele, Valentina Profumo, et al.
Current Treatment Options in Oncology|April 14, 2023
New Molecular Insights, and the Role of Systemic Therapies and Collaboration for Treatment of Epithelioid Hemangioendothelioma (EHE)Silvia Stacchiotti, William Tap, Hugh Leonard, et al.
Current Pharmaceutical Design|July 1, 2014
MicroRNA-dependent regulation of telomere maintenance mechanisms: a field as much unexplored as potentially promisingFrancesca Santambrogio, Paolo Gandellini, Graziella Cimino-Reale, et al.
Oncotarget|April 1, 2015
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecinsValentina Zuco, Michelandrea De Cesare, Nadia Zaffaroni, et al.
Current Pharmaceutical Design|September 15, 2012
Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathwayGiacomo Cossa, Laura Gatti, Giuliana Cassinelli, et al.
Cell Cycle (Georgetown, Tex.)|September 8, 2011
Characterization of novel antisense HIF-1α transcripts in human cancersDavide Bertozzi, Raffaella Iurlaro, Olivier Sordet, et al.
Cell Proliferation|September 14, 2021
δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosisFabrizio Fontana, Monica Marzagalli, Michela Raimondi, et al.
Current Medicinal Chemistry|April 7, 2016
Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer CellsCristina Corno, Laura Gatti, Cinzia Lanzi, et al.
Pageof 24

Showing results (41-50 of 234) with videos related to

Sort By:
Pageof 24
Current Topics in Medicinal Chemistry|December 27, 2011
RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapyMarzia Pennati, Enrico Millo, Paolo Gandellini, et al.
BMC Cancer|June 8, 2010
Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysisLorenza Venturini, Rosita Motta, Alessandro Gronchi, et al.
Current Medicinal Chemistry|February 16, 2013
MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targetsNicola Fenderico, Anna Casamichele, Valentina Profumo, et al.
Current Treatment Options in Oncology|April 14, 2023
New Molecular Insights, and the Role of Systemic Therapies and Collaboration for Treatment of Epithelioid Hemangioendothelioma (EHE)Silvia Stacchiotti, William Tap, Hugh Leonard, et al.
Current Pharmaceutical Design|July 1, 2014
MicroRNA-dependent regulation of telomere maintenance mechanisms: a field as much unexplored as potentially promisingFrancesca Santambrogio, Paolo Gandellini, Graziella Cimino-Reale, et al.
Oncotarget|April 1, 2015
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecinsValentina Zuco, Michelandrea De Cesare, Nadia Zaffaroni, et al.
Current Pharmaceutical Design|September 15, 2012
Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathwayGiacomo Cossa, Laura Gatti, Giuliana Cassinelli, et al.
Cell Cycle (Georgetown, Tex.)|September 8, 2011
Characterization of novel antisense HIF-1α transcripts in human cancersDavide Bertozzi, Raffaella Iurlaro, Olivier Sordet, et al.
Cell Proliferation|September 14, 2021
δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosisFabrizio Fontana, Monica Marzagalli, Michela Raimondi, et al.
Current Medicinal Chemistry|April 7, 2016
Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer CellsCristina Corno, Laura Gatti, Cinzia Lanzi, et al.
Pageof 24